HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Quantrill, S.J. Articles by Gokal, R. Search for Related Content PubMed PubMed Citation Articles by Quantrill, S.J. Articles by Gokal, R.

Side-effects of antituberculosis drug treatment in patients with chronic renal failure

¹ Depts of Respiratory Medicine and ² Renal Medicine, Manchester Royal Infirmary, Manchester, UK

CORRESPONDENCE: S. Quantrill, Dept of Cystic Fibrosis, Royal Brompton Hospital, Sydney Street, London, SW3 6NP, UK. Fax: 44 2073518052. E-mail: s.quantrill@ic.ac.uk

Keywords: chronic renal failure, dialysis, side-effects, tuberculosis

Received: November 27, 2001
Accepted February 6, 2002

Patients with chronic renal failure (CRF) have a high incidence of tuberculosis (TB). Those from the Indian subcontinent are at particular risk. The frequency of side-effects associated with antituberculous treatment in a group of patients with CRF was studied.

All cases of TB in patients with CRF occurring over a 13-yr period at the Manchester Royal Infirmary, from 1986–1999, were identified by diagnostic coding, microbiology records and a TB database. The case notes were then reviewed.

Twenty-four cases were identified, eight predialysis and 16 requiring regular dialysis. TB occurring in the dialysis group was extrapulmonary in every case. Nineteen of 24 (79%) patients were of Indian subcontinent origin and 14 of 16 (87%) dialysis patients were non-Caucasian. Adverse effects of treatment occurred in two of eight (25%) in the predialysis group and nine of 16 (56%) of the dialysis group. These were most commonly neuropsychiatric (6), hepatic (4) and gastrointestinal (4). Neuropsychiatric symptoms occurred exclusively in dialysis patients.

In conclusion, a high incidence of side-effects from antituberculous medication, especially neuropsychiatric, hepatic and gastrointestinal, was identified in patients with chronic renal failure. Careful monitoring for side-effects is essential in this group, and consideration should be given to administering antituberculous chemoprophylaxis to all high-risk groups.